Adam Bonislawski

The method could offer a more accessible, less expensive way to measure the expression of hundreds of cell surface markers across millions of single cells.

CE has seen significant uptake within biopharma for characterization of intact proteins and has made inroads into both bottom-up and top-down proteomics.

The reporters could be useful in applications like synthetic biology and cell signaling studies and ultimately for highly multiplexed nanopore protein analysis.

The company has formed a proteomics advisory panel as it looks to explore applications for its ZipChip capillary electrophoresis device in proteomics research.

The company is building a blood-based glycoproteomic assay intended to help doctors predict which cancer patients will respond to checkpoint inhibitors.

The method could enable better measurement of histone PTMs in samples including cancer biopsies as well as analysis of tissue and tumor heterogeneity.

The study lays the groundwork for further work with academic and pharma partners on the clinical utility of the Vectra Polaris platform.

The tool uses peptide correlation analysis to detect differences in protein proteoform populations across different samples or experimental conditions.

Since the proteomics facility launched in 2019, revenues have roughly doubled each year and it has doubled its staff, with biopharma driving much of the demand.

The company is developing a protein sequencing approach that combines Edman degradation with amino acid specific probes for single-molecule analysis.